In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F [Read More…]
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
The United States FDA grants accelerated approval for Pfizer’s therapy for the treatment of blood cancer (type)-affected patients which is difficult to treat.
